-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, with the continuous implementation of the medical reform policy, in order to obtain living space, more and more pharmaceutical companies have begun to cut drug prices one after another
.
At present, many regions have issued notices announcing that some drugs have voluntarily applied for price reductions
.
On March 8, Qinghai Province issued a notice to adjust the prices of some medicines
.
The notice shows that due to the application of the enterprise, the prices of four drugs, including clarithromycin sustained-release tablets, enme trastuzumab for injection, and enme trastuzumab for injection, will be adjusted
.
It is understood that on February 10, Qinghai Province adjusted the price of Pazufloxacin Mesylate Sodium Chloride Injection from 29.
97 yuan to 26.
55 yuan according to the application of the enterprise
.
It is worth mentioning that it is found that not only Qinghai Province has recently issued a notice of "drug price reduction", but many provinces across the country have also issued relevant notices, and a large number of best-selling drugs are ushering in price reductions
.
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Among them, from the perspective of price reduction, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
On February 11, the Liaoning Provincial Centralized Purchasing Network for Medicines and Medical Consumables issued a notice that 33 medicines applied for an active price reduction, including Liuwei Dihuang Pills, Fuzi Lizhong Pills, and Zhibai Dihuang Pills.
The net price is 12 yuan, and the manufacturer is Shaanxi Tangwang Tianyang Pharmaceutical
.
On February 7, Jiangsu issued a notice of drug price adjustment.
34 drugs produced by 28 pharmaceutical companies ushered in price reductions.
Among them, vitamin D2 soft capsules (0.
125mg*10, produced by Nanjing Sea Whale) 48.
5 yuan will be reduced to 41 yuan, hypoglycemic drugs.
Glipizide controlled-release tablets (5mg*14, produced by Nanjing Yiheng) dropped from 28.
8 yuan to 28.
5 yuan
.
From the above point of view, the industry believes that many pharmaceutical companies are actively applying for price reductions, mainly due to the pressure of the market and policies
.
At present, the implementation of drug price correction and price limit listing has become an effective means to solve the falsely high drug prices and rectify the order of the pharmaceutical market
.
In this context, whether it is an unselected over-reviewed product or an original research drug, it cannot escape the fate of price reduction
.
In this regard, analysts predict that, according to the medical improvement development schedule and the policy documents released for many reforms, more and more pharmaceutical companies will take such measures one after another in the future, actively seeking price reductions in more cities, covering more markets
.
However, it is worth noting that in this context, the market and revenue of all generic drugs, related generic drugs, out-of-patent original drugs, and all generic drugs are expected to shrink significantly, and the pharmaceutical market pattern may also undergo more new changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
At present, many regions have issued notices announcing that some drugs have voluntarily applied for price reductions
.
On March 8, Qinghai Province issued a notice to adjust the prices of some medicines
.
The notice shows that due to the application of the enterprise, the prices of four drugs, including clarithromycin sustained-release tablets, enme trastuzumab for injection, and enme trastuzumab for injection, will be adjusted
.
It is understood that on February 10, Qinghai Province adjusted the price of Pazufloxacin Mesylate Sodium Chloride Injection from 29.
97 yuan to 26.
55 yuan according to the application of the enterprise
.
It is worth mentioning that it is found that not only Qinghai Province has recently issued a notice of "drug price reduction", but many provinces across the country have also issued relevant notices, and a large number of best-selling drugs are ushering in price reductions
.
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Among them, from the perspective of price reduction, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
On February 11, the Liaoning Provincial Centralized Purchasing Network for Medicines and Medical Consumables issued a notice that 33 medicines applied for an active price reduction, including Liuwei Dihuang Pills, Fuzi Lizhong Pills, and Zhibai Dihuang Pills.
The net price is 12 yuan, and the manufacturer is Shaanxi Tangwang Tianyang Pharmaceutical
.
On February 7, Jiangsu issued a notice of drug price adjustment.
34 drugs produced by 28 pharmaceutical companies ushered in price reductions.
Among them, vitamin D2 soft capsules (0.
125mg*10, produced by Nanjing Sea Whale) 48.
5 yuan will be reduced to 41 yuan, hypoglycemic drugs.
Glipizide controlled-release tablets (5mg*14, produced by Nanjing Yiheng) dropped from 28.
8 yuan to 28.
5 yuan
.
From the above point of view, the industry believes that many pharmaceutical companies are actively applying for price reductions, mainly due to the pressure of the market and policies
.
At present, the implementation of drug price correction and price limit listing has become an effective means to solve the falsely high drug prices and rectify the order of the pharmaceutical market
.
In this context, whether it is an unselected over-reviewed product or an original research drug, it cannot escape the fate of price reduction
.
In this regard, analysts predict that, according to the medical improvement development schedule and the policy documents released for many reforms, more and more pharmaceutical companies will take such measures one after another in the future, actively seeking price reductions in more cities, covering more markets
.
However, it is worth noting that in this context, the market and revenue of all generic drugs, related generic drugs, out-of-patent original drugs, and all generic drugs are expected to shrink significantly, and the pharmaceutical market pattern may also undergo more new changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
